Viridian Therapeutics (VRDN) Stock Price, News & Analysis

Company Overview

Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases. Both candidates are being evaluated in multiple clinical trials across North America and Europe, underscoring the company’s commitment to building a robust pipeline of precision biologics. Viridian’s research platform leverages advanced antibody engineering to enhance potency, selectivity and pharmacokinetic properties, supporting the development of differentiated therapies with the potential for best-in-class profiles.

Founded in 2020 and headquartered in Boston, Massachusetts, Viridian was established by a team of experienced biotechnology entrepreneurs and scientists. The company completed its initial public offering in 2021 to secure funding for clinical development and manufacturing scale-up. Under the leadership of Chief Executive Officer Mara Aspinall and Chief Medical Officer Michael Rosenzweig, Viridian has formed strategic partnerships with contract development and manufacturing organizations to support its late-stage programs. Viridian’s global footprint extends through clinical sites and collaborative networks aimed at delivering novel treatments to patients worldwide.

Key Stats

• Today's Range: $24.02 to $25.00
• 50-Day Range: $17.81 to $24.21
• 52-Week Range: $9.90 to $27.20
• Volume: 1.08 million shs
• Average Volume: 828,935 shs
• Market Capitalization: $1.97 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $34.88
• Consensus Rating: Moderate Buy

Viridian Therapeutics Stock Analysis - MarketRank™

Viridian Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 669th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Viridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Viridian Therapeutics has a consensus price target of $34.88, representing about 44.8% upside from its current price of $24.09.

Amount of Analyst Coverage

Viridian Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Viridian Therapeutics are expected to decrease in the coming year, from ($4.03) to ($4.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Viridian Therapeutics is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Viridian Therapeutics is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Viridian Therapeutics has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.54% of the outstanding shares of Viridian Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Viridian Therapeutics has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Viridian Therapeutics has recently decreased by 6.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Viridian Therapeutics does not currently pay a dividend.

Dividend Growth

Viridian Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.54% of the outstanding shares of Viridian Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Viridian Therapeutics has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Viridian Therapeutics has recently decreased by 6.91%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.30

News Sentiment

Viridian Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Viridian Therapeutics this week, compared to 5 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Viridian Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.65% of the stock of Viridian Therapeutics is held by insiders.

VRDN Stock Analysis - Frequently Asked Questions

How have VRDN shares performed this year?

Viridian Therapeutics' stock was trading at $19.17 at the beginning of 2025. Since then, VRDN shares have increased by 25.7% and is now trading at $24.09.

How were Viridian Therapeutics' earnings last quarter?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) posted its earnings results on Wednesday, August, 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.00). The firm's revenue was up 4.2% on a year-over-year basis.

Who are Viridian Therapeutics' major shareholders?

Top institutional shareholders of Viridian Therapeutics include Rice Hall James & Associates LLC (1.04%), Kopp Family Office LLC (0.24%), Simplify Asset Management Inc. (0.06%) and Voya Investment Management LLC (0.02%). Insiders that own company stock include Fairmount Funds Management Llc, Jonathan Violin, Scott Dunseth Myers, Lara Meisner, Stephen F Mahoney, Thomas W Beetham and Barrett Katz.
View institutional ownership trends.

How do I buy shares of Viridian Therapeutics?

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Viridian Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Viridian Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 10/21/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:VRDN
• CIK: 1590750
• Web: www.viridiantherapeutics.com
• Phone: (617) 272-4600
• Fax: 760-537-4101
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Viridian Therapeutics: $34.88
• High Price Target: $44.00
• Low Price Target: $26.00
• Potential Upside/Downside: +44.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$269.95 million
• Net Margins: -112,806.88%
• Pretax Margin: -112,806.88%
• Return on Equity: -78.95%
• Return on Assets: -49.91%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 11.01
• Quick Ratio: 11.01

Sales & Book Value

• Annual Sales: $300 thousand
• Price / Sales: 6,558.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.09 per share
• Price / Book: 3.96

Miscellaneous

• Outstanding Shares: 81,670,000
• Free Float: 81,137,000
• Market Cap: $1.97 billion
• Optionable: Optionable
• Beta: 0.49